Top Markets
#1 Celer Network Celer Network +49.10%
#2 Gravity Gravity +24.44%
#3 Galxe Galxe +23.88%
#4 ICON ICON +13.39%
#5 MemeCore MemeCore +13.25%
#6 Cartesi Cartesi +12.87%
#7 Zilliqa Zilliqa +10.95%
#8 Genius Genius +10.65%
#9 Ontology Gas Ontology Gas +9.33%
#10 CyberDEX CyberDEX +7.13%
Coin of the day
Celer Network Celer Network
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rangering i aksjer #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
Aksjekurs
$0.1559364
Sist synkronisert: 2026-09-18
Markedsverdi
$195.17K
Endring (1 dag)
6.60%
Endring (1 år)
-30.91%
Land
GB
Handel Fusion Antibodies plc (FAB)

Kategori

Healthcare
Inntekter for Fusion Antibodies plc (FAB)
Inntekter i Sep 2025 TTM: $-2.06M
Ifølge Fusion Antibodies plc sine nyeste økonomiske rapporter er selskapets nåværende resultat $-2.06M. I 2024 hadde selskapet et resultat på $-2.89M, en økning sammenlignet med resultatet i 2023, som var $-3.53M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Fusion Antibodies plc fra 2013 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -256,061.35%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -94,754.12%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B 149,694.82%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B 194,783.51%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH